myEPITOPE
Immunogenicity screening — High-precision immunogenicity prediction
myEPITOPE delivers accurate, scalable, biologically grounded immunogenicity prediction — enabling more potent immunotherapeutics. Built around our first-in-class high-precision immunogenicity prediction tool neoIM, it estimates the likelihood that MHC-I–presented epitopes elicit CD8⁺ T-cell responses. The algorithm outperforms existing tools and de-risks preclinical validation significantly.
What myEPITOPE delivers
We offer immunogenicity screening of epitopes with a turnaround time of 1 week:
- Presentation prediction: identification of target epitopes likely to be presented at the cell surface across various patient populations
- Immunogenicity hotspot identification: identification of high-impact immunogenic epitope clusters across the target sequence
- Similarity-to-self analysis: isolation of the target epitopes least related to the canonical human proteome
- Coverage estimation: fine-grained predictions of target population coverage for a select set of immunogenic epitopes
- myCONSTRUCT: next-generation string-of-beads design (optional)
- myRNA: next-generation codon optimization (optional)
Frequently asked questions about myEPITOPE
What is myEPITOPE?
myEPITOPE delivers biologically grounded immunogenicity prediction for MHC-I–presented epitopes using myNEO’s neoIM algorithm, helping de-risk preclinical validation.
What is the turnaround time for myEPITOPE?
Immunogenicity screening with myEPITOPE has a turnaround time of 1 week.
Is there a myEPITOPE technology paper?
Yes. myNEO publishes a technology paper on myEPITOPE immunogenicity prediction in the publications library.
Ready to use myEPITOPE?
Talk to our team about integrating myEPITOPE into your discovery or development workflow.